Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$12.8MMiss by $2.7M
EPS-$0.33Beat by $0.04
Revenue estimate$15.5M
EPS estimate-$0.37

Next report

Nov 5, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.24

Financials

Q3 2025

Income statement

See full
Revenue$12.8M+38.5%
Operating income-$33.0M-24.3%
Net income-$27.1M-13.5%
EPS (diluted)-$0.33-13.8%

Balance sheet

See full
Cash & equivalents$208.3M+65.9%
Total debt$40.2M-8.1%
Total equity$245.8M+19.7%
Total assets$459.8M+45.9%

Cash flow

See full
Operating cash flow$100.4M+578%
CapEx$651.0K+63.2%
Free cash flow$99.8M+566%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$457.64M+5.3%
Enterprise value$289.46M-17.9%
P/S2.5×-26.5×

Profitability

See full
FCF margin79.9%—

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio6.5×+0.5×

FAQ

When did Monte Rosa Therapeutics, Inc. report Q3 2025 earnings?
Monte Rosa Therapeutics, Inc. (GLUE) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Monte Rosa Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Monte Rosa Therapeutics, Inc. reported revenue of $12.8M and eps of $-0.33 for Q3 2025.
Did Monte Rosa Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $15.5M by $2.7M. EPS beat the consensus estimate of $-0.37 by $0.04.
How did Monte Rosa Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 38.5% from $9.2M a year earlier and eps declined 13.8% from $-0.29.
Where can I find Monte Rosa Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268042) and the 10-Q periodic report (0001193125-25-268045) directly on SEC EDGAR. The filing index links above go to sec.gov.